Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?

European Radiology

Volumn 22, Issue 4, 2012, Pages 938-946

  Mayerhoefer, Marius E ^a   Schuetz, Matthias ^a   Magnaldi, Silvia ^a   Weber, Michael ^a   Trattnig, Siegfried ^a   Karanikas, Georgios ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

(68)Ga DOTATOC; Contrast media; NET; PET CT

Indexed keywords

CONTRAST MEDIUM; GALLIUM 68; TETRAXETAN;

ABDOMINAL TUMOR; ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ABDOMINAL NEOPLASMS; ADULT; AGED; AGED, 80 AND OVER; CONTRAST MEDIA; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84861462239     PISSN: 09387994     EISSN: 14321084     Source Type: Journal    
DOI: 10.1007/s00330-011-2328-7     Document Type: Article

References (24)

1. Joseph S,Wang YZ, Boudreaux JP, Anthony LB, Campeau R, Raines D et al (2011) Neuroendocrine tumors: current recommendations for diagnosis and surgical management. Endocrinol Metab Clin North Am 40:205-231
2. Scarpa M, Prando D, Pozza A, Esposti ED, Castoro C, Angriman I (2011) A systematic review of diagnostic procedures to detect midgut neuroendocrine tumors. J Surg Oncol 102:877-888
3. Lawrence B, Gustafsson BI, Chan A, Svejda B, KiddM, Modlin IM (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 40:1-18
4. Seregni E, Chiti A, Bombardieri E (1998) Radionuclide imaging of neuroendocrine tumours: biological basis and diagnostic results. Eur J Nucl Med 25:639-658
5. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumors: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781-793
6. Elsayes KM, Menias CO, Bowerson M, Osman OM, Alkharouby AM, Hillen TJ (2011) Imaging of carcinoid tumors: spectrum of findings with pathologic and clinical correlation. J Comput Assist Tomogr 35:72-80
7. Strosberg JR, Cheema A, Kvols LK (2011) A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract. Cancer Control 18:127-137
8. Ambrosini V, Campana D, Tomassetti P, Grassetto G, Rubello D, Fanti S (2010) PET/CT with 68Gallium-DOTA-peptides in NET: An overview. Eur J Radiol. doi:10.1016/j.ejrad.2010.07.022
9. Bushnell DL, Baum RP (2011) Standard imaging techniques for neuroendocrine tumors. Endocrinol Metab Clin North Am 40:153-162
10. Paulson EK, McDermott VG, Keogan MT, DeLong DM, Frederick MG, Nelson RC (1998) Carcinoid metastases to the liver: role of triple-phase helical CT. Radiology 206:143-150
11. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C et al (2007) 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med 48:508-518
12. Ambrosini V, Nanni C, Zompatori M, Campana D, Tomassetti P, Castellucci P (2010) (68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 37:722-727
13. Kumar R, Sharma P, Garg P, Karunanithi S, Naswa N, Sharma R et al (2011) Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours. Eur Radiol 21:2408-2416
14. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V et al (2010) 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J Nucl Med 51:669-673
15. Ruf J, Heuck F, Schiefer J, Denecke T, Elgeti F, Pascher A et al (2010) Impact of Multiphase 68Ga-DOTATOC-PET/CT on therapy management in patients with neuroendocrine tumors. Neuroendocrinology 91:101-109
16. Breeman WA, de Jong M, de Blois E, Bernard BF, Konijnenberg M, Krenning EP (2005) Radiolabelling DOTA-peptides with 68Ga. Eur J Nucl Med Mol Imaging 32:478-485
17. Decristoforo C, Knopp R, von Guggenberg E, Rupprich M, Dreger T, Hess A et al (2007) A fully automated synthesis for the preparation of 68Ga-labelled peptides. Nucl Med Commun 28:870-875
18. Singh J, Daftary A (2008) Iodinated contrast media and their adverse reactions. J Nucl Med Technol 36:69-74
19. Castellucci P, Pou Ucha J, Fuccio C, Rubello D, Ambrosini V, Montini GC et al (2011) Incidence of Increased 68Ga-DOTANOC Uptake in the Pancreatic Head in a Large Series of Extrapancreatic NET Patients Studied with Sequential PET/CT. J Nucl Med 52:886-890
20. Nakamoto Y, Nogami M, Sugihara R, Sugimura K, Senda M, Togashi K (2011) Is contrast material needed after treatment of malignant lymphoma in positron emission tomography/computed tomography? Ann Nucl Med 25:93-99
21. Pfluger T, Melzer HI, Schneider V, La Fougere C, Coppenrath E, Berking C et al (2011) PET/CT in malignant melanoma: contrastenhanced CT versus plain low-dose CT. Eur J Nucl Med Mol Imaging 38:822-831
22. Ruf J, Schiefer J, Furth C, Kosiek O, Kropf S, Heuck F et al (2011) 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT Phases of a triple-phase protocol. J Nucl Med 52:697-704
23. Veit-Haibach P, Schiesser M, Soyka J, Strobel K, Schaefer NG, Hesselmann R et al (2011) Clinical value of a combined multiphase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component. Eur Radiol 21:256-264
24. Kitajima K, Suzuki K, Nakamoto Y, Onishi Y, Sakamoto S, Senda M et al (2010) Low-dose non-enhanced CT versus full-dose contrast-enhanced CT in integrated PET/CT studies for the diagnosis of uterine cancer recurrence. Eur J Nucl Med Mol Imaging 37:1490-1498